Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Net Income (2018 - 2025)

Historic Net Income for Serina Therapeutics (SER) over the last 8 years, with Q3 2025 value amounting to -$6.4 million.

  • Serina Therapeutics' Net Income fell 2008.26% to -$6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.4 million, marking a year-over-year decrease of 9589.72%. This contributed to the annual value of -$17.6 million for FY2024, which is 37664.77% down from last year.
  • Per Serina Therapeutics' latest filing, its Net Income stood at -$6.4 million for Q3 2025, which was down 2008.26% from -$5.6 million recorded in Q2 2025.
  • Serina Therapeutics' Net Income's 5-year high stood at $65000.0 during Q4 2023, with a 5-year trough of -$6.4 million in Q3 2025.
  • Moreover, its 5-year median value for Net Income was -$2.7 million (2022), whereas its average is -$3.1 million.
  • In the last 5 years, Serina Therapeutics' Net Income skyrocketed by 10235.51% in 2023 and then plummeted by 866307.69% in 2024.
  • Quarter analysis of 5 years shows Serina Therapeutics' Net Income stood at -$103000.0 in 2021, then tumbled by 2579.61% to -$2.8 million in 2022, then soared by 102.36% to $65000.0 in 2023, then crashed by 8663.08% to -$5.6 million in 2024, then dropped by 14.95% to -$6.4 million in 2025.
  • Its last three reported values are -$6.4 million in Q3 2025, -$5.6 million for Q2 2025, and -$5.9 million during Q1 2025.